Colorectal News and Research

RSS

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

A new report from the American Cancer Society details cancer control efforts and outlines improvements as well as gaps in preventive behavior that contribute to cancer mortality.

21 May 2011

The Chartis Group and HPMG partner to help providers improve outpatient care delivery systems

HealthPartners Medical Group and Clinics and The Chartis Group today announce a unique collaboration to help hospitals and health systems achieve superior performance in health care quality and patient service, while simultaneously lowering costs.

20 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Use of a simple, at-home screening test by Canadians can prevent many unnecessary colorectal cancer deaths, according to a special report about colorectal cancer in Canadian Cancer Statistics 2011 released today by the Canadian Cancer Society, in collaboration with the Public Health Agency of Canada and Statistics Canada.

19 May 2011

Mayo Clinic develops new screening procedure for Lynch syndrome detection

Mayo Clinic has developed a screening procedure that could dramatically increase testing for Lynch syndrome, a hereditary genetic disorder that raises cancer risk, particularly for colorectal cancer.

19 May 2011

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG in combination with cetuximab as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer.

19 May 2011

MDxHealth reduces first quarter net loss by 17%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the quarter ended March 31, 2011.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Researchers help explain why smart drugs are not effective in some cancer patients

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor, and found that a decoy receptor might be limiting the amount of drug that gets to the intended target.

12 May 2011

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

As one of the first medical centers in the Northwest to perform robotic-assisted surgery, Swedish is home to the fastest growing, most comprehensive and experienced robotic-assisted surgical program in the region. Swedish established the multidisciplinary, robotic-assisted surgical program in 2005 and has since performed more than 3,400 robotic-assisted surgeries -- more than any other program in the region.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

Study: Many patients screened for colon cancer more often than recommended

Many patients are getting screened for colorectal cancer more often than guidelines recommend, hints a new study.

11 May 2011

U.S. veterans over 70 and older can benefit from current colon cancer screening methods

A new study of U.S. veterans ages 70 and older finds that the healthiest get the most benefit from current colon cancer screening methods. However, for many less healthy veterans the burdens of screening may outweigh the benefits.

10 May 2011

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Epigenomics AG, the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of Gastroenterology and Hepatology at the School of Medicine of Stanford University, has presented the results of a health economic analysis of potential future colorectal cancer screening with Septin9 blood tests at the ongoing Digestive Disease Week 2011.

9 May 2011

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc. today announced the signing of an agreement under which Merrimack has acquired the rights to develop and commercialize MM-398 in Europe and Asia.

9 May 2011

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a global provider of innovative life science solutions.

7 May 2011

Colorectal News and Research

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Coordinated efforts required to close gaps in preventive behavior: American Cancer Society

The Chartis Group and HPMG partner to help providers improve outpatient care delivery systems

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Simple home-based colon cancer screening test can prevent many unnecessary deaths in Canada

Mayo Clinic develops new screening procedure for Lynch syndrome detection

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

MDxHealth reduces first quarter net loss by 17%

Aeterna Zentaris first quarter revenues increase to $7.4 million

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Researchers help explain why smart drugs are not effective in some cancer patients

Swedish adds new virtual reality training simulator to help surgeons practice on robotic-assisted system

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Study: Many patients screened for colon cancer more often than recommended

U.S. veterans over 70 and older can benefit from current colon cancer screening methods

Epigenomics presents Septin9 blood test study data in colorectal cancer at DDW 2011

Merrimack acquires development and commercialization rights to MM-398 in Europe, Asia

Epigenomics, Life Technologies enter supply agreement for second-generation colorectal cancer blood test

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News